Bending the asthma cost curve: Is optimizing medication the answer?

弯曲哮喘成本曲线：优化药物治疗是答案吗？

• 批准号: 8488611
• 负责人: Matthew A Rank
• 金额: $ 9.9万
• 依托单位: MAYO CLINIC ARIZONA
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2014-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8488611
• 关键词: Bending; asthma; cost; curve; optimizing

PROJECT SUMMARY/ABSTRACT Stepping down asthma medications is a chronic disease management strategy that may limit potential side effects, reduce treatment burden, and decrease costs. Our preliminary findings suggest that we may not be treating some individuals with enough asthma medications and treating others with more than they need. We hypothesize that individuals with stable asthma who step down their asthma medications will have similar asthma outcomes and decreased total medical expenditures compared to those that do not step down asthma medication. We will use individuals participating in the nationally representative Medical Expenditure Panel Survey to compare 1 year baseline asthma medication dispensing, asthma exacerbation rates, and medical expenditures to the subsequent year in the same individuals. Understanding which strategies are effective for saving money and maintaining favorable clinical outcomes is important for individuals with asthma who have experienced increasing costs associated with managing their disease.

项目摘要/摘要 停用哮喘药物是一种慢性病管理策略，可能 减少潜在副作用，减轻治疗负担，降低成本。我们的 初步研究结果表明，我们可能没有对一些人进行足够的治疗 哮喘药物和治疗其他人超过他们需要的药物。我们假设 缓解期哮喘患者停用哮喘药物后也会有类似的症状 与哮喘患者相比，哮喘患者的转归和总医疗费用降低 而不是停用哮喘药物。我们将利用个人参与全国范围的 具有代表性的医疗费用小组调查比较1年基线哮喘 药物分配、哮喘加重率和医疗费用 第二年，在相同的个人。了解哪些策略是有效的 因为节省资金和保持良好的临床结果对 经历过与以下疾病相关的成本增加的哮喘患者 管理他们的疾病。